Practice Management News

A phase 2 randomized clinical trial found that ceftolozane/tazobactam was a safe and effective option for the treatment of children with complicated UTIs, researchers reported in The Pediatric Infectious Disease Journal.

An FDA advisory committee voted unanimously Thursday in favor of a plan to streamline and simplify COVID-19 vaccine compositions in the United States by replacing initial, primary doses with the bivalent vaccines currently used as boosters.

Massachusetts health officials detected a novel strain of gonorrhea with reduced susceptibility or resistance to five antibiotic classes — the first of its kind in the United States.

A record number of Americans — 16.3 million — signed up for health insurance through Affordable Care Act Marketplaces in 2023, the Biden-Harris administration announced Wednesday.

The FDA Antimicrobial Drugs Advisory Committee voted on Wednesday 14-1 in favor of the use of rezafungin for the treatment of candidemia and invasive candidiasis.

Amazon has further expanded its reach into health care with a new discount prescription drug program.

As the COVID-19 pandemic heads into its 4th year, it is a good time to reflect on strides made for those with mild-to-moderate disease not requiring hospitalization.

Shorter durations of antibiotic therapy are now recommended for many infections. Although practice has begun to change, the “shorter is better” mantra has not reached all prescribers.

What drew me to infectious diseases was the potentially enormous impact it has — not only on individuals but on societies.

Long-acting cabotegravir and rilpivirine dosed every 8 weeks was effective and well tolerated, showing noninferiority to the standard 4-week dosing at 152 weeks, according to extended data from the ATLAS-2M trial.